the aid library

LIST OPTIONS

Filter

2523

Sort by:

Direction:

Download (120)

View PDF (176)

Repository of resources on disability inclusion and Covid-19

Coregroup; International Disability and Development Consortium (IDDC) Coregroup; International Disability and Development Consortium (IDDC) (2020) C2

Last update: 2 April 2020

Download (121)

View PDF (128)

Camp/site management interim operational guidance for COVID -19 readiness and response

UN High Commissioner for Refugees UNHCR (2020) C2

Frequently asked questions (FAQs) This document highlights COVID-19 specific considerations in relation to camp and camp-like settings, and is intended to assist in guiding operations where camp/site management5 is being implemented. Although the guidance - structured around questions from the fiel... more

Download (81)

View PDF (115)

Operationalizing Protection during COVID-19 - Case Studies and Practices from the Field

Reliefweb; OCHA Services; UN High Commissioner for Refugees (UNHCR) (2020) CC

27 March 2020 Countrys: World and Kenya, Zambia, Ethiopia The restrictions on movement imposed as a result of the COVID-19 pandemic constitute one of the largest single global challenges that the humanitarian community has ever encountered. Maintaining continuity and quality in the delivery of e... more

Download (147)

View PDF (192)

COVID-19 Supply Chain System:Requesting and Receiving Supplies

World Health Organisation (2020) C_WHO

The global COVID-19 outbreak is leading to an acute and drastic shortage of essential supplies, including personal protective equipment, diagnostics and clinical management. At the request of the UN Secretary-General and in support of the UN Crisis Management Team, a Supply Chain Tas... more

Download (121)

View PDF (187)

Considerations and Principles for Shielding People at High Risk of Severe Outcomes from COVID-19

Social Science in Humanitarian Action (2020) CC

This brief considers the rationale for shielding individuals at high risk of severe disease or death from COVID-19 in low- and middleincome countries. It provides an overview of proposed approaches to shielding, discusses the categories of individuals who may be identified for shielding, and outline... more

Download (152)

View PDF (170)

Developing Key Messages for Communities on GBV & COVID-19

Protection Cluster, UNFPA (2020) CC

In humanitarian settings, tailoring community engagement interventions for gender, language, and local culture improves communities’ uptake with interventions. Measures taken to prevent and respond to COVID-19 pandemic such as confinement may increase GBV, especially domestic violence and Intimate... more

Download (138)

View PDF (160)

Disability Considerations in GBV Programming during the COVID-19 Pandemic

Pearce E. Protection Cluster, UNFPA (2020) CC

This note provides information and practical guidance to support gender-based violence (GBV) practitioners to integrate attention to disability into GBV prevention, risk mitigation and response efforts during the COVID-19 pandemic. This document complements other resources relating to GBV and COVID-... more

Download (131)

View PDF (125)

Cadre de valeurs du SAGE de l’OMS pour l’attribution des vaccins anti-COVID-19 et la détermination des groupes à vacciner en priorité, 14 septembre 2020

World Health Organization WHO (2020) C_WHO

The WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination is intended to offer guidance on the prioritization of groups for vaccination when vaccine supply is limited. It provides a values foundation for the objectives of COVID-19 vaccination programmes and links t... more

Download (117)

View PDF (192)

COVID-19 Scientific and Public Health Policy Update – (6 July 2022)

African Union; Africa CDC Centres for Disease Control and Prevention (2022) C1

This bi-weekly brief details the latest developments in scientific knowledge and public health policy from around the world as well as updates to the COVID-19-related guidance from Africa CDC, WHO and other public health agencies.

Download (164)

View PDF (139)

Note d’orientation de l’OMS : Prise en charge clinique de la COVID-19

Organisation mondiale de la santé (OMS) (2022) C_WHO

Les notes d’orientation décrivent les mesures essentielles que les décideurs nationaux et infranationaux peuvent mettre en place concernant les aspects suivants de la lutte contre la COVID-19 : les tests de diagnostic, la prise en charge clinique, la réalisation des cibles en matière de vaccin... more

Download (115)

View PDF (136)

Note d’orientation de l’OMS : tests de diagnostic de la COVID-19

Organisation Mondiale de la Santé OMS (2022) C_WHO

Les notes d’orientation exposent les mesures essentielles que les décideurs peuvent mettre en œuvre aux niveaux national et infranational pour les éléments suivants : tests de diagnostic de la COVID-19, prise en charge clinique de la COVID-19, atteinte des cibles en matière de vaccination con... more

Download (90)

View PDF (141)

Risk communication and community engagement: a compendium of case studies in times of COVID-19

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

This collection of case studies on risk communication and community engagement (‎RCCE)‎ from 18 different country/area level public health partners in the WHO European Region provides evidence of numerous results achieved and lessons learned since the start of the COVID-19 pandemic. RCCE has not... more

Download (203)

View PDF (230)

Gender based violence and sexual and reproductive health during the Covid-19 pandemic in the pacific region

United Nations Population Fund UNFPA (2022) C1

Sexual and reproductive health is health issues that have to do with your body, sex, relationships, and having and giving birth to children. This includes having the information you need to be able to make your own decisions about your body, when to have sex, and whether or not to become a parent. T... more

Download (126)

View PDF (193)

Africaʼs response to the COVID-19 pandemic. A summary of country reports

World Health Organization WHO, Regional Office of Africa (2022) C_WHO

January 2020 to December 2021

Download (106)

View PDF (140)

Weekly epidemiological update on COVID-19 - 4 January 2023

World Health Organization WHO (2023) C_WHO

Globally, more than 3 million new cases and 10 000 deaths have been reported in the week of 26 December 2022 to 1 January 2023. This represents a reduction in weekly cases and deaths of 22% and 12%, respectively. In the last 28 days (5 December 2022 to 1 January 2023), over 14.5 million cases and ov... more

Download (152)

View PDF (306)

Écart de rémunération entre femmes et hommes dans le secteur de la santé et des soins : une analyse de la situation dans le monde à l’ère de la COVID-19

World Health Organisation (WHO) (2022) C_WHO

Le secteur de la santé et des soins constitue une source d’emploi considérable dans le monde, en particulier pour les femmes. Les personnels de santé et d’aide à la personne représentent environ 3,4 % de la population active mondiale, notamment quelque 10 % dans les pays à revenu élevé e... more

Download (160)

View PDF (205)

Modelling COVID-19 vaccination status and adherence to public health and social measures, Eastern Mediterranean Region and Algeria

World Health Organisation (WHO) (2023) C_WHO

The introduction of vaccines for coronavirus disease 2019 (COVID-19) added another measure to the existing set of recommended preventive measures (wearing a mask in public, keeping a distance from other people and regular handwashing). The roll-out of the vaccines, however, raised concerns that vac... more

Download (114)

View PDF (144)

Inclusión de las personas mayores en la planificación para emergencias: Perspectivas durante y después de la pandemia de COVID-19

World Health Organisation (WHO) (2023) C_WHO

En la Región de las Américas, las poblaciones están envejeciendo y se está experimentando una rápida transición demográfica. El índice de envejecimiento, que refleja el tamaño de los grupos de mayor edad por 100 en comparación con los menores de 15 años, demuestra claramente el aumento de... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (16)

View PDF (24)

Access to NCD medicines: emergent issues during the COVID-19 pandemic and key structural factors 2023

World Health Organization WHO (2023) C_WHO

The coronavirus disease (COVID-19) pandemic exacerbated pre-existing inequalities in the treatment and care of noncommunicable diseases (NCDs). This report examines the effect of the COVID-19 pandemic on access to NCD medicines, and the policies and strategies implemented by countries and health sys... more